The Division of Signal Transduction Therapy or DSTT is an organization managed by the University of Dundee, the Medical Research Council, and the pharmaceutical companies AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, Janssen Pharmaceutica, and Pfizer. The purpose of the collaboration is to conduct cell signalling research and to encourage development of new drug treatments for global diseases such as cancer, rheumatoid arthritis, and Parkinson’s Disease.